Is Bimzelx Approved for Psoriasis?
Yes, Bimzelx (bimekizumab-bkzx) is FDA-approved for moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. The approval came in October 2023, based on Phase 3 trials showing superior skin clearance compared to placebo and other biologics like adalimumab.[1][2]
How Does Bimzelx Work for Psoriasis?
Bimzelx is a monoclonal antibody that blocks both IL-17A and IL-17F, cytokines driving inflammation in plaque psoriasis. This dual inhibition leads to faster and deeper responses than drugs targeting only IL-17A, with 85-91% of patients achieving PASI 90 (90% skin clearance) by week 16 in trials.[2][3]
Who Qualifies for Bimzelx Treatment?
It's for adults with moderate to severe plaque psoriasis not controlled by topical therapies. Not recommended for mild cases or as first-line. Contraindicated in active infections like tuberculosis; screening required.[1][4]
How Does Bimzelx Compare to Other Psoriasis Drugs?
| Drug | Target | Dosing | PASI 90 Rate (Week 16) | Key Edge |
|------|--------|--------|-------------------------|----------|
| Bimzelx | IL-17A/F | 320 mg every 4 weeks (then every 8) | 85-91% | Dual blockade, subcutaneous |
| Cosentyx (secukinumab) | IL-17A | 300 mg every 4 weeks | 70-80% | Established safety data |
| Taltz (ixekizumab) | IL-17A | 160 mg load, then 80 mg every 4 weeks | 70-80% | Similar efficacy, more frequent dosing |
| Tremfya (guselkumab) | IL-23 | 100 mg every 8 weeks | 70-80% | Longer intervals, joint psoriasis data |
Bimzelx shows higher clearance rates but has a newer safety profile.[2][5]
What Side Effects Do Patients Report?
Common: upper respiratory infections (15-20%), oral candidiasis (7-14%, due to IL-17 role in antifungal defense), injection site reactions. Serious risks include hypersensitivity and IBD flares. Monitor for infections; no increased malignancy signal in trials.[1][3]
Is Bimzelx Approved for Other Conditions?
Yes, also for active psoriatic arthritis (2024) and axial spondyloarthritis. Not approved for Crohn's or ulcerative colitis due to IBD risks.[1][6]
When Does Bimzelx Patent Protection End?
U.S. composition of matter patent (U.S. Patent 8,119,600) expires in 2028, with formulation patents extending to 2037. Potential for Paragraph IV challenges from biosimilar developers.[7]
[1]: FDA Label - Bimzelx (bimekizumab-bkzx) - https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761032s000lbl.pdf
[2]: BE VIVID/BE READY Trials - NEJM (2021) - https://www.nejm.org/doi/full/10.1056/NEJMoa2102373
[3]: Bimzelx Prescribing Information - UCB - https://www.bimzelx.com/psoriasis
[4]: American Academy of Dermatology Guidelines - https://www.aad.org/member/clinical-quality/guidelines/psoriasis
[5]: Head-to-Head Comparisons - J Am Acad Dermatol (2023) - https://www.jaad.org/article/S0190-9622(23)00456-7/fulltext
[6]: FDA Approval History - PsA/axSpA - https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-bimekizumab-bkzx-psoriatic-arthritis
[7]: DrugPatentWatch.com - Bimzelx Patents - https://www.drugpatentwatch.com/p/tradename/BIMZELX